CA2299139C - 4-phenyl-pyridine derivatives - Google Patents

4-phenyl-pyridine derivatives Download PDF

Info

Publication number
CA2299139C
CA2299139C CA2299139A CA2299139A CA2299139C CA 2299139 C CA2299139 C CA 2299139C CA 2299139 A CA2299139 A CA 2299139A CA 2299139 A CA2299139 A CA 2299139A CA 2299139 C CA2299139 C CA 2299139C
Authority
CA
Canada
Prior art keywords
methyl
trifluoromethyl
bis
tolyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2299139A
Other languages
English (en)
French (fr)
Other versions
CA2299139A1 (en
Inventor
Michael Bos
Quirico Branca
Guido Galley
Thierry Godel
Torsten Hoffmann
Walter Hunkeler
Patrick Schnider
Heinz Stadler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2299139A1 publication Critical patent/CA2299139A1/en
Application granted granted Critical
Publication of CA2299139C publication Critical patent/CA2299139C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
CA2299139A 1999-02-24 2000-02-23 4-phenyl-pyridine derivatives Expired - Lifetime CA2299139C (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP99103504 1999-02-24
EP99123689.4 1999-11-29
EP99123689 1999-11-29
EP99103504.9 1999-11-29

Publications (2)

Publication Number Publication Date
CA2299139A1 CA2299139A1 (en) 2000-08-24
CA2299139C true CA2299139C (en) 2011-03-29

Family

ID=26152908

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2299139A Expired - Lifetime CA2299139C (en) 1999-02-24 2000-02-23 4-phenyl-pyridine derivatives

Country Status (54)

Country Link
US (2) US6297375B1 (en:Method)
EP (2) EP1035115B1 (en:Method)
JP (1) JP3399900B2 (en:Method)
KR (1) KR100384904B1 (en:Method)
CN (1) CN1142144C (en:Method)
AR (2) AR029614A1 (en:Method)
AT (2) ATE277905T1 (en:Method)
AU (1) AU767048B2 (en:Method)
BE (1) BE2015C057I2 (en:Method)
BG (1) BG64554B1 (en:Method)
BR (1) BRPI0000908B8 (en:Method)
CA (1) CA2299139C (en:Method)
CY (3) CY1111317T1 (en:Method)
CZ (1) CZ300596B6 (en:Method)
DE (3) DE60014216T2 (en:Method)
DK (2) DK1394150T3 (en:Method)
EA (1) EA003673B1 (en:Method)
EG (1) EG23817A (en:Method)
ES (3) ES2226622T3 (en:Method)
FR (2) FR2790473B1 (en:Method)
GB (1) GB2347422A (en:Method)
GE (1) GEP20022676B (en:Method)
GT (1) GT200000017A (en:Method)
HR (2) HRP20000097B1 (en:Method)
HU (1) HU227629B1 (en:Method)
IL (1) IL134654A (en:Method)
IS (1) IS2116B (en:Method)
IT (1) IT1320763B1 (en:Method)
JO (1) JO2294B1 (en:Method)
LT (1) LTC1035115I2 (en:Method)
LU (1) LU92745I2 (en:Method)
MA (1) MA26722A1 (en:Method)
ME (1) ME00593B (en:Method)
MY (2) MY123648A (en:Method)
NL (1) NL300758I2 (en:Method)
NO (1) NO315554B1 (en:Method)
NZ (1) NZ502948A (en:Method)
OA (1) OA11680A (en:Method)
PA (1) PA8491101A1 (en:Method)
PE (1) PE20001467A1 (en:Method)
PL (1) PL217311B1 (en:Method)
PT (2) PT1035115E (en:Method)
RS (3) RS20080562A (en:Method)
SE (1) SE1035115T5 (en:Method)
SG (1) SG91856A1 (en:Method)
SI (1) SI1035115T1 (en:Method)
SK (2) SK287912B6 (en:Method)
SV (1) SV2002000024A (en:Method)
TN (1) TNSN00032A1 (en:Method)
TR (1) TR200000520A3 (en:Method)
TW (1) TWI288746B (en:Method)
UA (1) UA71547C2 (en:Method)
UY (1) UY32314A (en:Method)
ZA (1) ZA200000894B (en:Method)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058640A2 (en) * 1998-05-11 1999-11-18 Philadelphia Health And Education Corporation Mct-1, a human oncogene
AU767123B2 (en) 1999-02-24 2003-10-30 F. Hoffmann-La Roche Ag Phenyl- and pyridinyl derivatives
US6291465B1 (en) * 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
ATE253561T1 (de) * 1999-11-29 2003-11-15 Hoffmann La Roche 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-( - morpholin-4-yl-4-o-tolyl-pyridin-3-yl)- isobutyramid
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
JP3938651B2 (ja) * 2000-04-13 2007-06-27 セントラル硝子株式会社 光学活性α−メチル−ビス−３、５−（トリフルオロメチル）ベンジルアミンの製造方法
KR100501608B1 (ko) * 2000-07-14 2005-07-18 에프. 호프만-라 로슈 아게 4-페닐-피리딘 유도체의 ｎｋ1 수용체의 길항성선구약물로서의 ｎ-산화물
TWI287003B (en) 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
CA2431397C (en) * 2000-12-14 2007-05-01 F. Hoffmann-La Roche Ag Self emulsifying lipid matrix (selm)
US6531597B2 (en) * 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
DE60220997T2 (de) * 2001-03-27 2008-03-13 Eisai R&D Management Co., Ltd. N-aryl-substituiertes cyclisches aminderivat und medizin, die dieses als wirkstoff enthält
WO2002085458A2 (en) * 2001-04-23 2002-10-31 F. Hoffman-La Roche Ag Use of nk-1 receptor antagonists against benign prostatic hyperplasia
EP1763350B1 (en) * 2004-07-06 2011-12-21 Xenon Pharmaceuticals Inc. Nicotinamide derivatives and their use as therapeutic agents
WO2002100434A1 (en) * 2001-06-07 2002-12-19 The General Hospital Corporation Treatment of neuropathic pain with n-methyl-d-aspartate (nmda) receptor antagonists
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
AU2002340847B2 (en) * 2001-09-10 2007-09-13 F. Hoffmann-La Roche Ag Oily thixotropic formulations
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
JP2006508061A (ja) 2002-09-20 2006-03-09 ファイザー・プロダクツ・インク エストロゲン受容体に対するアミドおよびスルホンアミドリガンド
EP1567497B1 (en) 2002-12-06 2009-09-23 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
US8729107B2 (en) * 2002-12-06 2014-05-20 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
DE602004007486T2 (de) 2003-01-31 2008-04-30 F. Hoffmann-La Roche Ag Neue kristallmodifikation von 2-(3,5-bis-trifluormethyl-phenyl)-n-6-(1,1-dioxo-1lamda-6-thiomorpholin-4-yl)-4(4-fluor-2-methyl-phenyl)-pyridin-3-yl-n-methyl-isobutyramid
CA2530886C (en) * 2003-07-03 2013-05-28 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists for treating schizophrenia
TWI280239B (en) * 2003-07-15 2007-05-01 Hoffmann La Roche Process for preparation of pyridine derivatives
CA2533899C (en) 2003-07-30 2011-01-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
MX2007000198A (es) * 2004-07-06 2007-03-15 Hoffmann La Roche Proceso para la preparacion de derivados de carboxamida-piridina utilizados como intermediarios en la sintesis de antagonistas del receptor nk-1.
KR100881240B1 (ko) * 2004-07-06 2009-02-05 에프. 호프만-라 로슈 아게 Ｎｋ-1 수용체 길항제의 합성에 있어서 중간체로서사용되는 카르복스아미드 피리딘 유도체의 제조 방법
US20060030556A1 (en) * 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation, including testosterone deficiency
WO2006013205A1 (en) * 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
BRPI0515482A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seus usos como agentes terapêuticos
TW200626592A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
TW200626154A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CN101084211A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为治疗剂的用途
TW200624427A (en) 2004-09-20 2006-07-16 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
US7569725B2 (en) * 2004-10-21 2009-08-04 Britsol-Myers Squibb Company Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US20060135636A1 (en) * 2004-11-15 2006-06-22 Honeywell International Inc. Isocyanate-based polymer foams with nano-scale materials
US7176205B2 (en) 2005-02-22 2007-02-13 Hoffmann-La Roche Inc. Bi-pyridinyl derivatives as NK-1 antagonists
JP2008531592A (ja) * 2005-02-24 2008-08-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ カリウムイオンチャンネル開口薬としての新規なピリジン誘導体
EP2281556A1 (en) 2005-02-25 2011-02-09 F. Hoffmann-La Roche AG Tablets with improved drugs substance dispersibility
DE602006005624D1 (de) * 2005-03-23 2009-04-23 Hoffmann La Roche Metaboliten für nk-i-antagonisten zur emesis
CA2618646A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
RU2008109031A (ru) * 2005-08-11 2009-09-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы муковисцидозного трансмембранного регулятора проводимости
TWI378101B (en) 2005-09-09 2012-12-01 Glaxosmithkline Llc Pyridine derivatives and their use in the treatment of psychotic disorders
DE602006011485D1 (de) * 2005-09-23 2010-02-11 Hoffmann La Roche Neue dosierformulierung
PL2395002T3 (pl) * 2005-11-08 2015-04-30 Vertex Pharma Kompozycja farmaceutyczna zawierająca heterocykliczny modulator transporterów zawierających kasetę wiążącą ATP
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7872022B2 (en) * 2006-04-03 2011-01-18 Hoffmann-La Roche Inc. Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
SI2007756T1 (sl) 2006-04-07 2015-11-30 Vertex Pharmaceuticals Incorporated Modulatorji prenašalcev z atp-vezavno kaseto
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
CN102863432B (zh) 2007-05-09 2016-09-07 沃泰克斯药物股份有限公司 Cftr调节剂
HUE032268T2 (en) 2007-12-07 2017-09-28 Vertex Pharma Process for the preparation of cycloalkylcarboxamidopyridine benzoic acids
PL2225230T3 (pl) 2007-12-07 2017-08-31 Vertex Pharmaceuticals Incorporated Stałe postacie kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-ilo)cyklopropanokarboksyamido)-3-metylopirydyn-2-ylo)benzoesowego
EP2249650A4 (en) * 2008-02-19 2012-01-11 Glaxosmithkline Llc ANILINOPYRIDINE AS A FAK HEMMER
EP2271622B1 (en) 2008-02-28 2017-10-04 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as CFTR Modulators
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
GB0814340D0 (en) 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
CN102639536B (zh) * 2009-08-27 2015-03-18 尼尔医疗有限公司 吡啶衍生物的无水晶型
NZ599439A (en) 2009-11-18 2014-06-27 Helsinn Healthcare Sa Compositions and methods for treating centrally mediated nausea and vomiting
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
TW201143768A (en) * 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
EP2555754B1 (en) 2010-04-07 2016-04-06 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
EP2555755B2 (en) 2010-04-07 2019-07-10 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
CA3108488A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
EP2560488B1 (en) * 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
US20140155419A1 (en) * 2011-07-29 2014-06-05 Erkan Baloglu Compounds and methods
EP2747560A4 (en) * 2011-07-29 2015-02-25 Tempero Pharmaceuticals Inc CONNECTIONS AND METHODS
JP2014530249A (ja) 2011-10-18 2014-11-17 ヘルシン ヘルスケア ソシエテ アノニム ネツピタントおよびパロノセトロンの治療学的組合せ
AU2012335714B2 (en) 2011-11-08 2017-04-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
WO2014014841A1 (en) 2012-07-16 2014-01-23 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
RU2673084C2 (ru) 2013-11-08 2018-11-22 Киссеи Фармасьютикал Ко., Лтд. Производное карбоксиметилпиперидина
HRP20210516T2 (hr) 2013-11-12 2021-10-01 Vertex Pharmaceuticals Incorporated Postupak proizvodnje farmaceutskih pripravaka za liječenje bolesti koje su posredovane putem cftr
CN110840847B (zh) 2014-04-15 2022-07-29 沃泰克斯药物股份有限公司 用于治疗囊性纤维化跨膜传导调节因子介导的疾病的药物组合物
US20150315149A1 (en) * 2014-05-05 2015-11-05 Apicore Us Llc Methods of making netupitant and intermediates thereof
TWI649307B (zh) * 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
TW201613888A (en) * 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist
RS62259B1 (sr) 2014-11-18 2021-09-30 Vertex Pharma Proces izvođenja ispitivanja visoke propusnosti tečne hromatografije visokih performansi
WO2016141341A1 (en) 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
CN105061303A (zh) * 2015-08-03 2015-11-18 成都欣捷高新技术开发有限公司 一种制备奈妥吡坦关键中间体n-甲基-4-(2-甲基苯基)-6-(4-甲基-1-哌嗪基)-3-吡啶胺的新方法
EP4019018A1 (en) 2015-09-11 2022-06-29 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
KR20180090302A (ko) * 2015-12-07 2018-08-10 깃세이 야쿠힌 고교 가부시키가이샤 Nk1 수용체 길항제
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
CN106892864A (zh) * 2015-12-21 2017-06-27 上海科胜药物研发有限公司 一种奈妥皮坦游离碱的晶型a及其制备方法
CN115531553A (zh) * 2015-12-22 2022-12-30 武田药品工业株式会社 内体g蛋白-偶联的受体的三部分调节剂
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
US11266633B2 (en) 2017-06-30 2022-03-08 Chase Therapeutics Corporation NK-1 antagonist compositions and methods for use in treating depression
CN109384712B (zh) * 2017-08-14 2021-05-07 北京宽厚医药科技有限公司 靶向nk1受体拮抗剂及其在化疗所致恶心、呕吐治疗中的应用
EP3672964A4 (en) 2017-08-21 2021-05-26 Leiutis Pharmaceuticals Pvt. Ltd. Novel triple combination formulations for antiemetic therapy
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
KR20250140634A (ko) * 2018-09-28 2025-09-25 반다 파마슈티칼즈, 인코퍼레이티드. 멀미에서의 트라디피탄트의 용도
EP3902793A4 (en) * 2018-12-24 2022-09-07 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) MANUFACTURE OF A CHEMICAL COMPOUND, NEW FORM OF SALT, AND ASSOCIATED THERAPEUTIC USES
CN112174881B (zh) * 2019-07-04 2022-06-21 上海森辉医药有限公司 一种奈妥匹坦的衍生物及其制备方法
KR20220050956A (ko) * 2019-08-23 2022-04-25 유스트랄리스 파마슈티칼스 리미티드 (트레이딩 애즈 프레스수라 뉴로) 치료 방법 및 이의 용도
CN115427033B (zh) 2020-04-03 2024-08-09 尼尔医疗有限公司 用于治疗选自脓毒症、脓毒症休克、急性呼吸窘迫综合征(ards)或多器官功能障碍综合征(mods)的疾病的nk-1受体拮抗剂
CA3177477A1 (en) 2020-06-02 2021-12-09 Nerre Therapeutics Limited Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs
US12097197B2 (en) 2021-12-21 2024-09-24 Slayback Pharma Llc Stable liquid compositions of netupitant and palonosetron
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron
KR20250125376A (ko) 2022-12-12 2025-08-21 알프레드 이. 티펜바흐어 게엠베하 운트 ＆ 코. 카게 네투피탄트 및 팔로노세트론을 포함하는 고정 용량 복합제
WO2024126408A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Antioxidant-free fixed dose combination of netupitant and palonosetron

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1557420A (en) 1977-03-10 1979-12-12 Soc D Etudes Prod Chimique Preparation of isobutyramide derivatives
KR810001320B1 (ko) 1977-03-17 1981-10-14 삐에르 위브 신규한 이소부티라미드류의 제조방법
KR810001697B1 (ko) 1978-02-06 1981-10-27 삐에르 위브 이소부티라미드 유도체의 신규한 제조방법
EP0089153B1 (en) 1982-03-17 1986-09-24 Smith Kline & French Laboratories Limited Pyridine derivatives
US4745123A (en) * 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
GB8607312D0 (en) 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
GB8607313D0 (en) 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
CA1339423C (en) 1988-09-14 1997-09-02 Yuji Ono Pyridine compounds and pharmaceutical use thereof
US4994456A (en) 1989-03-01 1991-02-19 Nisshin Flour Milling Co., Ltd. Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
US4973597A (en) 1989-06-30 1990-11-27 Eli Lilly And Company Anticonvulsant agents
HU207047B (en) 1989-11-07 1993-03-01 Richter Gedeon Vegyeszet Process for producing new pyridine derivatives and pharmaceutical copositions comprising same
US5364943A (en) 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
GB9021056D0 (en) 1990-09-27 1990-11-07 Pfizer Ltd Antiarrhythmic agents
GB9214120D0 (en) 1991-07-25 1992-08-12 Ici Plc Therapeutic amides
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
AU4718093A (en) 1992-07-31 1994-03-03 Merck Sharp & Dohme Limited Substituted amines as tachykinin receptor antagonists
US5387595A (en) 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
GB9305672D0 (en) 1993-03-19 1993-05-05 Wyeth John & Brother Ltd Amide derivatives
NZ264063A (en) 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
IL112134A (en) 1993-12-29 1999-12-22 Merck Sharp & Dohme Substituted morpholine derivatives their preparation and pharmaceutical compositions containing them
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
EE03445B1 (et) 1994-06-06 2001-06-15 Warner-Lambert Company Tahükiniini (NK1) retseptori antagonistid
US6294537B1 (en) 1995-03-17 2001-09-25 Sanofi-Synthelabo Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools
NO309272B1 (no) * 1995-03-24 2001-01-08 Takeda Chemical Industries Ltd Cykliske forbindelser, preparater inneholdende forbindelsene samt mellomprodukter for fremstilling av forbindelsene
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
NZ326874A (en) 1996-03-29 2000-01-28 Pfizer 6-phenylpyridyl-2-amine derivatives
AU4885097A (en) 1996-11-08 1998-06-03 Sankyo Company Limited Arylureas or arylmethylcarbamoyl derivatives
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
AU767123B2 (en) * 1999-02-24 2003-10-30 F. Hoffmann-La Roche Ag Phenyl- and pyridinyl derivatives
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
ATE253561T1 (de) * 1999-11-29 2003-11-15 Hoffmann La Roche 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-( - morpholin-4-yl-4-o-tolyl-pyridin-3-yl)- isobutyramid

Also Published As

Publication number Publication date
CZ300596B6 (cs) 2009-06-24
KR100384904B1 (ko) 2003-05-22
BR0000908B1 (pt) 2013-09-24
LTPA2015036I1 (lt) 2015-11-25
RS53869B1 (sr) 2015-08-31
MEP5709A (en) 2011-12-20
DK1394150T3 (da) 2011-03-21
IS2116B (is) 2006-06-15
SG91856A1 (en) 2002-10-15
GB0003908D0 (en) 2000-04-05
CY2015042I1 (el) 2016-06-22
EP1035115A1 (en) 2000-09-13
HUP0000748A2 (en) 2001-03-28
BG64554B1 (bg) 2005-07-29
TR200000520A2 (tr) 2001-06-21
DK1035115T3 (da) 2005-01-24
NO315554B1 (no) 2003-09-22
ITMI20000328A1 (it) 2001-08-23
AU1946800A (en) 2000-08-31
BRPI0000908B8 (pt) 2021-05-25
PL217311B1 (pl) 2014-07-31
US6297375B1 (en) 2001-10-02
NO20000885L (no) 2000-08-25
ES2226622T3 (es) 2005-04-01
GB2347422A (en) 2000-09-06
SE1035115T5 (sv) 2015-08-04
CZ2000609A3 (cs) 2001-01-17
GT200000017A (es) 2001-08-15
SK2352000A3 (en) 2000-09-12
HU0000748D0 (en) 2000-04-28
MA26722A1 (fr) 2004-12-20
NZ502948A (en) 2001-09-28
LTC1035115I2 (lt) 2017-04-10
CY2015041I1 (el) 2016-06-22
LU92745I2 (fr) 2015-08-17
EP1394150A1 (en) 2004-03-03
CY2015041I2 (el) 2016-06-22
CN1270959A (zh) 2000-10-25
CY1111317T1 (el) 2015-08-05
US6479483B2 (en) 2002-11-12
DE10008042A1 (de) 2000-08-31
ATE277905T1 (de) 2004-10-15
FR15C0049I1 (fr) 2015-08-28
EP1035115B1 (en) 2004-09-29
RS50194B (sr) 2009-05-06
PE20001467A1 (es) 2000-12-20
EA200000155A2 (ru) 2000-08-28
JO2294B1 (en) 2005-09-12
EP1394150B1 (en) 2011-01-19
TR200000520A3 (tr) 2001-06-21
TWI288746B (en) 2007-10-21
IS5381A (is) 2000-08-25
HRP20080306B1 (hr) 2015-01-30
KR20000062599A (ko) 2000-10-25
HUP0000748A3 (en) 2003-12-29
SK287911B6 (sk) 2012-03-02
ZA200000894B (en) 2000-08-24
HK1031223A1 (en) 2001-06-08
RS20080562A (sr) 2009-09-08
BG104187A (en) 2000-11-30
ES2171109B2 (es) 2003-09-16
IT1320763B1 (it) 2003-12-10
SV2002000024A (es) 2002-01-23
IL134654A (en) 2011-03-31
CN1142144C (zh) 2004-03-17
EG23817A (en) 2007-09-19
OA11680A (fr) 2005-01-12
GEP20022676B (en) 2002-04-25
PA8491101A1 (es) 2001-04-30
SE1035115T3 (sv) 2005-01-18
HRP20000097A2 (en) 2001-10-31
US20020091265A1 (en) 2002-07-11
JP3399900B2 (ja) 2003-04-21
DE60014216D1 (de) 2004-11-04
CA2299139A1 (en) 2000-08-24
TNSN00032A1 (fr) 2005-11-10
HU227629B1 (en) 2011-10-28
ES2171109A1 (es) 2002-08-16
PL338598A1 (en) 2000-08-28
NL300758I1 (en:Method) 2015-12-22
ITMI20000328A0 (it) 2000-02-23
AR029614A1 (es) 2003-07-10
UA71547C2 (uk) 2004-12-15
SK287912B6 (sk) 2012-03-02
FR2790473B1 (fr) 2004-04-02
NO20000885D0 (no) 2000-02-23
DE60045564D1 (de) 2011-03-03
MY123648A (en) 2006-05-31
HRP20000097B1 (en) 2008-12-31
AR062949A2 (es) 2008-12-17
DE60014216T2 (de) 2006-03-02
FR2790473A1 (fr) 2000-09-08
HRP20080306A2 (en) 2008-11-30
UY32314A (es) 2010-02-26
ES2359235T3 (es) 2011-05-19
FR15C0049I2 (fr) 2016-02-12
MY147451A (en) 2012-12-14
BE2015C057I2 (en:Method) 2019-03-06
ATE496032T1 (de) 2011-02-15
IL134654A0 (en) 2001-04-30
YU9500A (sh) 2002-11-15
NL300758I2 (en:Method) 2015-12-22
BR0000908A (pt) 2000-09-12
SI1035115T1 (en) 2005-02-28
PT1035115E (pt) 2005-01-31
EA200000155A3 (ru) 2000-12-25
EA003673B1 (ru) 2003-08-28
JP2000247957A (ja) 2000-09-12
AU767048B2 (en) 2003-10-30
PT1394150E (pt) 2011-02-17
ME00593B (me) 2015-08-31

Similar Documents

Publication Publication Date Title
CA2299139C (en) 4-phenyl-pyridine derivatives
CA2364662C (en) 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists
CA2415890C (en) N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
CA2416874C (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
AU3422500A (en) Phenyl- and pyridinyl derivatives
MXPA00001849A (en) 4-phenylpyridine derivatives and their use as nk-1 receptor antagonists
MXPA01008511A (es) Derivados de 3-fenilpiridina y su uso como antagonistas del receptor de la neuroquinina (nk-1)

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20200224